Potency of Gp96-Ig/Fc-OX40L cell-based combination vaccine in cancer immunotherapy

被引：0
|
作者：
Xu, Xin
Gonzalez, Louise E.
Fromm, George J.
de Silva, Suresh
Giffin, Louise
Rose, Jason
Schreiber, Taylor H.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
605
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Generation of a novel, allogeneic cell-based, Gp96-Ig/OX40L cancer vaccine, improves anti-tumor immunity and long-term memory T-cell generation
    Tahiliani, Vikas
    Miriyala, Jayalakshmi
    Dillon, Patrick
    Rose, Jason
    Giffin, Louise
    Hutchins, Jeff
    Seavey, Matthew M.
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Combined intratumoral electroporation and allogeneic vaccination of Gp96-Ig/Fc-OX40L stimulates CD8 T cell cross-priming to tumor specific neoantigens and enhanced anti-tumor response
    de Silva, Suresh
    Fromm, George
    Mukhopadhyay, Anandaroop
    Campbell, Jean
    Pierce, Robert
    Schreiber, Taylor
    CANCER RESEARCH, 2017, 77
  • [3] Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
    Padula, Laura
    Fisher, Eva
    Rivas, Katelyn
    Podack, Kristin
    Frasca, Daniela
    Kupritz, Jonah
    Seavey, Matthew M.
    Jayaraman, Padmini
    Dixon, Eric
    Jasuja, Rahul
    Strbo, Natasa
    VACCINE: X, 2022, 12
  • [4] Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
    Fromm, George
    de Silva, Suresh
    Giffin, Louise
    Xu, Xin
    Rose, Jason
    Schreiber, Taylor H.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (09) : 766 - 778
  • [5] Gp96-Ig/Costimulator combination vaccine improves T cell priming, enhances immunity, memory, and tumor elimination
    Gonzalez, Louis
    Giffin, Louise
    Rose, Jason
    Fromm, George
    De Silva, Suresh
    Schreiber, Taylor
    Hutchins, Jeff
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [6] Effect on anti-tumor immunity and long-term memory CD8+T-cell generation with a novel, allogeneic cell based, Gp96-Ig/OX40L cancer vaccine.
    Hutchins, Jeff
    Tahiliani, Vikas
    Miriyala, Jayalakshmi
    Rose, Jason
    Dillon, Patrick
    Seavey, Matthew M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Immunotherapy meets epigenetics: GP96-Ig cellular vaccine genetic signature is modulated by the inhibition of histone modifications
    Fromm, George J.
    Schilling, Neal
    Schreiber, Taylor H.
    CANCER RESEARCH, 2015, 75
  • [8] Gp96-Ig/Costimulator Combination Platform Improves T Cell Priming, Enhances Immunity and Memory
    Gonzalez, Louis E.
    Giffin, Louise
    Rose, Jason
    Fromm, George
    Da Silva, Suresh
    Schreiber, Taylor H.
    Jasuja, Rahul
    Hutchins, Jeff
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [9] Gp96-Ig/costimulator combination platform improves T cell priming and enhances immunity, memory, and tumor elimination
    Giffin, Louise
    Gonzalez, Louis
    Rose, Jason
    Hutchins, Jeff
    CANCER RESEARCH, 2018, 78 (13)
  • [10] An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas
    Murphy, Katherine A.
    Lechner, Melissa G.
    Popescu, Flavia E.
    Bedi, Jessica
    Decker, Stacy A.
    Hu, Peisheng
    Erickson, Jami R.
    O'Sullivan, M. Gerard
    Swier, Lauryn
    Salazar, Andres M.
    Olin, Michael R.
    Epstein, Alan L.
    Ohlfest, John R.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4657 - 4668
12345